Clinical trials: asthma
Asthma
Clinical Study to Evaluate the Efficacy and Safety of VR506 Using a New Inhaler for the Treatment of Asthma
To evaluate the clinical efficacy, safety, tolerability and dose-response relationship, using oral corticosteroid (OCS) modulation, of 3 different doses of VR506 using a twice daily regimen from a new dry powder inhaler (nDPI)…
- Trial name
- NCT01720069
- Testing
- VR506
- Where
- 77 sites in United States, Bulgaria and 6 more
- Volunteers
- 197 people
- Sponsor
- Vectura Limited
Asthma
Non-interventional Surveillance of Effectiveness of Symbicort® Maintenance And Reliever Therapy (Symbicort® SMART) in the Treatment of Moderate and Severe Asthma
This is a 3-month non-interventional, observational study on patients with moderate and severe asthma.
- Trial name
- NCT00573222
- Testing
- Symbicort
- Where
- 13 sites in Croatia
- Volunteers
- 330 people
- Sponsor
- AstraZeneca
Asthma
Local Phase 4 Pan-European SMART Study
The purpose of this study is to evaluate the effect of two different maintenance doses of Symbicort Maintenance And Reliever Therapy (SMART) in adult asthmatic patients. A 6 month treatment period
- Trial name
- NCT00463866
- Testing
- Budesonide/formoterol
- Where
- 817 sites in Belgium, Finland and 12 more
- Volunteers
- 8,424 people
- Sponsor
- AstraZeneca
Asthma
A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg
The purpose is to investigate the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared with Budesonide pMDI 80 μg, 2 Actuations Twice Daily, in Children Ages 6 to <12 Years with Asthma during 12…
- Trial name
- CHASE 3 (NCT02091986)
- Testing
- Symbicort pMDI, Budesonide pMDI
- Where
- 70 sites in United States, Mexico and 2 more
- Volunteers
- 882 people
- Sponsor
- AstraZeneca
Asthma
A Two-week Study Assessing the Onset of Effect Questionnaire (OEQ) Administered Daily Versus Weekly in Adult Subjects
The purpose of this study is to demonstrate whether subjects respond similarly to the Onset of Effect Questionnaire (OEQ) using a 1 week recall period versus a 1 day recall period.
- Trial name
- NCT00449527
- Testing
- Budesonide/formoterol pMDI, Budesonide HFA pMDI
- Where
- 44 sites in United States
- Volunteers
- 123 people
- Sponsor
- AstraZeneca
Asthma, Chronic Obstructive Pulmonary Disease
Inspiratory Flow Parameters of Easyhaler and Diskus Inhalers (SALIF)
The purpose of this study is to characterise inspiratory flow parameters across 2 Easyhaler® (EH) inhaler versions and Diskus® inhaler in patients with asthma (including children, adults, and the elderly) and in patients with…
- Trial name
- SALIF (NCT01424137)
- Testing
- Easyhaler type A, Easyhaler type B, Diskus inhaler
- Where
- 5 sites in Estonia, Finland
- Volunteers
- 227 people
- Sponsor
- Orion Corporation, Orion Pharma
Severe Asthma
Evaluate the Pharmacokinetics of BAT2606 Injection in Healthy Chinese Male Subjects
To evaluate the pharmacokinetics, safety and immunogenicity of BAT2606 in healthy China male subjects.
- Trial name
- NCT05576454
- Testing
- Mepolizumab Injection (BAT2606 Injection), Mepolizumab Injection (EU-licensed Nucala), Mepolizumab Injection (US-licensed Nucala)
- Where
- China
- Volunteers
- 207 people, healthy volunteers welcome
- Sponsor
- Bio-Thera Solutions
Severe Eosinophilic Asthma
Real World Study With Benralizumab in Severe Asthma in Switzerland
BEEPS describes the utility of patient reported outcomes (PRO) as simple, pragmatic, and sensitive tool to assess early treatment response of benralizumab to document the level of asthma control and change in medication after 1…
- Trial name
- BEEPS (NCT03907137)
- Where
- 12 sites in Switzerland
- Volunteers
- 79 people
- Sponsor
- AstraZeneca
Asthma
Cost-effectiveness Study of Symbicort as Maintenance and Reliever Therapy (SMART)
This study is an economic evaluation of Symbicort (Budesonide/formoterol) as maintenance and reliever therapy (SMART) versus its competitive alternatives.
- Trial name
- NCT00937066
- Where
- Colombia
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Asthma
A Study to Establish the Efficacy of QBX258 in Patients With Moderate to Severe Asthma
This study is designed to investigate the efficacy and safety of QBX258 in subjects with moderate to severe asthma.
- Trial name
- NCT01479595
- Testing
- QBX258
- Where
- 20 sites in United States, Germany and 1 more
- Volunteers
- 65 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
The primary purpose of this study is to evaluate the effects of Fluticasone Furoate (FF)/ Umeclidinium (UMEC)/ Vilanterol (VI) on lung function compared with FF/VI after 24 weeks of treatment.
- Trial name
- NCT05757102
- Testing
- FF/UMEC/VI, ELLIPTA, FF/VI
- Where
- 67 sites in United States, Argentina and 7 more
- Volunteers
- 138 people
- Sponsor
- GlaxoSmithKline
Asthma
4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma
The primary goal of this trial is to compare the efficacy and safety of COMBIVENT CFC MDI with albuterol HFA MDI, the current standard reliever medication in asthma.
- Trial name
- NCT00818454
- Testing
- Combivent CFC MDI, Albuterol HFA MDI, Respimat Combivent
- Where
- 41 sites in United States
- Volunteers
- 226 people
- Sponsor
- Boehringer Ingelheim
Eosinophilic Asthma
A Multi-dose Study on the Safety and Efficacy of Self-administered Intranasal AD17002 Treatment for Eosinophilic Asthma
1. Eosinophilic asthma, a type 2 immune disorder, often involves the excessive production of type 2 cytokines. 2. Excessive Type 2 cytokines lead to chronic inflammation, airway hyperresponsiveness, and airflow obstruction. 3.
- Trial name
- NCT07250594
- Testing
- AD17002, Formulation buffer
- Where
- Taiwan
- Volunteers
- 126 people
- Sponsor
- Advagene Biopharma Co. Ltd.
Asthma
The Study of Omalizumab (CMAB007 and Xolair) in Healthy Subjects to Compare the PK, PD and Safety
A phase 1, randomized, double-blind, parallel group, single-dose study to compare the pharmacokinetics, pharmacodynamics and safety of two formulations of Omalizumab (CMAB007 and Xolair) in healthy subjects.
- Trial name
- NCT04778137
- Testing
- Omalizumab
- Where
- China
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
Asthma, Bronchospasm
Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006
The main objective is to evaluate the bronchodilatory efficacy, safety and pharmacokinetic profiles of A006 (Albuterol Dry Powder Inhaler (DPI)), in comparison with those of an active control, Proventil-HFA (Albuterol Metered…
- Conditions
- Asthma, Bronchospasm, Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT01189396
- Testing
- A006, Proventil-HFA
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Asthma
Single Dose Clinical Trial of MG-ZG122 in Chinese Healthy Adult Subjects
To determine the safety and tolerability of MG-ZG122 in Chinese healthy adult subjects
- Trial name
- NCT05659927
- Testing
- MG-ZG122 Humanized Monoclonal Antibody Injection
- Where
- China
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
Allergic Asthma, Uncontrolled Moderate to Severe
Efficacy and Safety of Zerafil® (Omalizumab) in Participants With Uncontrolled Moderate to Severe Allergic Asthma
The purpose of this study is to evaluate the efficacy and safety of Omalizumab produced by CinnaGen compared with Xolair® (Genentech, Inc., USA And Novartis Pharmaceuticals Corp, Switzerland) in subjects with uncontrolled…
- Trial name
- NCT05813470
- Testing
- Omalizumab (CinnaGen), Omalizumab (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland)
- Where
- 22 sites in Iran
- Volunteers
- 256 people
- Sponsor
- Cinnagen
Asthma
Symbicort Usage in Asthma Treatment and Impact of a New Therapeutic Strategy on Compliance and Asthma Control in France
Descriptive pharmacoepidemiological study on the use of Symbicort Turbuhaler in the treatment of asthma in France and impact of a new therapeutic strategy on the compliance and control of asthma
- Trial name
- SYMBIOSE (NCT00812357)
- Where
- 168 sites in France
- Volunteers
- 579 people
- Sponsor
- AstraZeneca
Severe Asthma
A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)
The purpose of this study is to evaluate the efficacy and safety of verekitug (UPB-101) in participants with severe asthma. The study will evaluate the incidence of asthma exacerbations, other pharmacodynamic (PD) parameters such…
- Trial name
- NCT06196879
- Testing
- Verekitug (UPB-101)
- Where
- 155 sites in United States, Argentina and 13 more
- Volunteers
- 479 people
- Sponsor
- Upstream Bio Inc.
Asthma
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Trail Evaluating the Efficacy and Safety of GR1802 Injection in Patients with Moderate to Severe Asthma
This is a multi-center, randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of GR1802 injection in comparison to placebo in patients with atopic dermatitis.
- Trial name
- NCT06642961
- Testing
- GR1802 injection
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.